drugset / Trial / NCT04991870
Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood \[CB\]-NK-TGF-betaR2-/NR3C1-) in treating patients with glioblastoma that has come back (recurrent). CB-NK-TGF-betaR2-/NR3C1- cells are genetically changed immune cells that may help to control the disease.
Timeline
- Start
- 2023-04-28
- Primary completion
- 2027-01-31
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cord Blood-derived Expanded Allogeneic Natural Killer Cells | Cell therapy | — | Other |